CONTEXT: Report of a retrospective registry on the use of Neovasc Reducer ( a coronary stent) in the treatment of chronic refractory angina, published in the Journal of Cardiology. The headline grabbing “Largest Real-World Registry” does fall a little flat when you see the 658 patients whose data was extracted from 20 centers in Europe, The United Kingdom and Israel. Note the United Kingdom is no longer consider to be geographically part of Europe.
IMPACT: Low
READ TIME: 2 mins
Quality Level Mean [1 – 10]: 7
1. “We are delighted by the real-world evidence that supports our unique and innovative Reducer therapy as a safe and effective option that can now provide relief and an improved quality of life for many of these patients that previously had no further treatment Reducer is CE-marked in the European Union for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary arteries deliver an inadequate supply of blood to the heart muscle, despite treatment with standard revascularization or cardiac drug therapies.”
2. “The article , authored by Francesco Ponticelli, M.D., Maria Cecilia Hospital, Cotignola, Italy, describes long-term outcomes of patients suffering from refractory angina treated with the Neovasc Reducer™ system.”
3. “The authors described the study as the largest international real-world registry of patients with refractory angina who were treated with the coronary sinus Reducer.”
4. “Forward-looking statements may involve, but are not limited to, Reducer’s safety and ability to help patients suffering from refractory angina feel better and the growing cardiovascular marketplace.”